AGL vs CVS
AGL: Agilon health partners with primary care physicians to modernize their practices and shift them toward value-based care models for Medicare Advantage populations. CVS: A leading health solutions company integrating retail pharmacy, pharmacy benefit management, and insurance services to manage health costs and improve access to care.
Side-by-side fundamentals
| Metric | AGL | CVS | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $91.72 | $94.75 | |
| Market cap | $1.5B | $121.2B | |
| P/E as of 2026-10-20 | n/a | 25.00 | |
| Net margin FY2025, SEC XBRL | -6.6% | +0.4% | CVS higher |
| Operating margin FY2025, SEC XBRL | -7.8% | +1.2% | CVS higher |
| ROE FY2025, SEC XBRL | -308.8% | +2.4% | CVS higher |
| ROA FY2025, SEC XBRL | -30.8% | +0.7% | CVS higher |
| Debt / equity | 0.13 | 0.77 | AGL lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -2.1% | +7.8% | CVS higher |
| Revenue CAGR (3y) SEC XBRL | +35.4% | +7.6% | AGL higher |
| Dividend yield as of 2026-09-03 | n/a | +3.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 19 | CVS higher |
| Beta as of 2026-09-03 | 0.71 | 0.28 | |
| 1-year return as of 2026-10-20 close | +270.6% | +14.9% | AGL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.